Easy To Use Patents Search & Patent Lawyer Directory

At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.

Searching:





Search by keyword, patent number, inventor, assignee, city or state:




Patent # Description
2018/0142051 INITIATOR COMPOSITION FOR FLUORINATED POLYMER AND METHOD FOR PRODUCING FLUORINATED POLYMER
To provide a polymerization initiator composition for a fluorinated polymer which will not destroy ozone layer and which has less influence over polymerization...
2018/0142050 FLUOROELASTOMER COMPOSITION
The invention pertains to a fluoroelastomer composition [composition (C)] comprising:--at least one fluoroelastomer [fluoroelastomer (A)];--at least one basic...
2018/0142049 METHOD OF PREPARING AROMATIC VINYL-UNSATURATED NITRILE-BASED COPOLYMER AND AROMATIC VINYL-UNSATURATED...
The present invention provides a method of preparing an aromatic vinyl-unsaturated nitrile-based copolymer in which, when an aromatic vinyl-unsaturated...
2018/0142048 PROCESS TO PRODUCE MODIFIED CLAY, MODIFIED CLAY PRODUCED AND USE THEREOF
An intercalated, modified and calcined smectite clay comprising (a) pillars comprising aluminum and: (i) at least one rare earth or lanthanide group metal; or...
2018/0142047 PROCESS TO PRODUCE MODIFIED CLAY, SUPPORTED METALLOCENE POLYMERIZATION CATALYST, CATALYST PRODUCED AND USE THEREOF
Catalyst support-activator for olefin polymerization catalysts, and processes for making, the support-activator comprising an intercalated, modified and...
2018/0142046 Catalyst System Comprising Supported Alumoxane and Unsupported Alumoxane Particles
The invention is directed to a supported olefin polymerization catalyst system comprising catalyst compound, silica support and alumoxane activator, where part...
2018/0142045 Catalyst System Containing High Surface Area Supports and Sequential Polymerization to Produce Heterophasic...
This invention relates to propylene polymers having multimodal molecular weight distribution and propylene polymerization processes using single site catalyst...
2018/0142044 CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS
A solid catalyst component for the polymerization of olefins, made from or containing Mg, Ti and an electron donor of formula (I) ##STR00001## where...
2018/0142043 PRODUCTION METHODS FOR AQUEOUS EMULSION, FINE POWDER AND STRETCHED POROUS BODY OF MODIFIED POLYTETRAFLUOROETHYLENE
To provide a production method for an aqueous emulsion of modified polytetrafluoroethylene which is environmentally friendly and which is suitable for...
2018/0142042 METHOD FOR PREPARING HIGH PERFORMANCE TREAD RUBBERS THROUGH FILLER SILYLATION REACTION CATALYZED IN SITU BY...
The present invention discloses a method for preparing high-performance tread rubber through a filler silylation reaction catalyzed in situ by an ionic liquid....
2018/0142041 Dilute Filtration Sterilization Process for Viscoelastic Biopolymers
Manufactured hyaluronic acid products are used in numerous surgical applications including viscoelastic supplementation for the treatment of osteoarthritis;...
2018/0142040 NOVEL HETERODIMERIC PROTEINS
The invention provides novel heterodimeric proteins including heterodimeric antibodies.f5
2018/0142039 METHOD FOR INCREASING THE PERCENTAGE OF MONOMERIC ANTIBODY FAB-DSFV MULTIMERIC SPECIES
The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in...
2018/0142038 ANTI-GLYCOPROTEIN ANTIBODIES AND USES THEREOF
A new class of antibodies having specificity for glycoproteins are described. The antibodies are shown to bind sensitively and specifically to mannosylated...
2018/0142037 MUTANT INTERLEUKIN-2 POLYPEPTIDES
The present invention generally relates to mutant interleukin-2 polypeptides that exhibit reduced affinity to the .alpha.-subunit of the IL-2 receptor, for use...
2018/0142036 COMPOSITION ENRICHED IN ANTI-A AND/OR ANTI-B POLYCLONAL IMMUNOGLOBULINS FOR USE IN THE TREATMENT OF AUTOIMMUNE...
The invention relates to a composition strongly enriched with anti-A and/or anti-B polyclonal immunoglobulins, comprising polyclonal human immunoglobulins,...
2018/0142035 COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
Compositions, e.g., compositions comprising cellular therapeutics and/or protein therapeutics, and methods of using such compositions for treating cancer are...
2018/0142034 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
Provided herein are chimeric antigen receptors (CARs) comprising an antigen binding domain (e.g., CD19, CD30, GD2, etc.), transmembrane domain (e.g., CD28),...
2018/0142033 CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO
The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis...
2018/0142032 ANTI-LAMP1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES, AND USES THEREOF
Antibodies are provided which specifically bind human and Macaca fascicularis lysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates...
2018/0142031 Smart CAR Devices, DE CAR Polypeptides, Side CARs and Uses Thereof
The present invention relates generally to the field of RNA Control Devices and/or destabilizing elements (DE) combined with Chimeric Antigen Receptors (CARs)...
2018/0142030 ANTIBODIES TO CD40
Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with...
2018/0142029 HUMAN CGRP RECEPTOR BINDING PROTEINS
Antigen binding proteins that bind to human CGRP receptor (CGRP R) are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells...
2018/0142028 METHODS FOR IDENTIFYING IMMUNOBINDERS OF CELL-SURFACE ANTIGENS
The invention provides methods for identifying immunobinders, such as scFv antibodies, capable of specifically binding to cell surface antigens, and...
2018/0142027 METHOD OF MODIFYING ISOELECTRIC POINT OF ANTIBODY VIA AMINO ACID SUBSTITUTION IN CDR
The present inventors provide methods for modifying the isoelectric point of an antibody while retaining its antigen-binding activity, comprising modifying the...
2018/0142026 METHOD FOR THE TREATMENT OF NEUROLOGICAL DISEASE
The present invention pertain an inhibitor of CSF-1R activity for use in the treatment and/or prophylaxis of neurologic diseases and new method of treatment of...
2018/0142025 DIAGNOSTIC TEST INVOLVING ANTI-CD25-ADC
The present disclosure relates to determining the eligibility of subjects for treatment and particularly, although not exclusively, to selecting subjects for...
2018/0142024 ANTI-cMET ANTIBODY
The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine...
2018/0142023 COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE
Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one...
2018/0142022 ANTI-PD-1 ANTIBODIES, COMPOSITIONS COMPRISING ANTI-PD-1 ANTIBODIES AND METHODS OF USING ANTI-PD-1 ANTIBODIES
Provided herein are antibodies that selectively bind to PD-1 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are...
2018/0142021 BISPECIFIC ANTIBODY CONSTRUCTS FOR CDH3 AND CD3
The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target...
2018/0142020 SINGLE DOMAIN ANTIBODIES TARGETING CD1D
The invention relates to compounds, in particular polypeptides that specifically bind to the non-classical MHC protein CD1d and modulate CD1d-mediated...
2018/0142019 THERAPEUTIC CD47 ANTIBODIES
Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to...
2018/0142018 ANTI-CD19 ANTIBODIES AND METHODS OF USE THEREOF
The disclosure relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind...
2018/0142017 Methods for Treating Corneal and Conjunctival Inflammation and Inflammatory Disorders
Provided herein are methods for reducing corneal inflammation, reducing inflammatory cell (e.g., dendritic cell) recruitment to the cornea, and treating an...
2018/0142016 ANTI-ROR1 ANTIBODIES
The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to...
2018/0142015 METHODS, COMPOSITIONS AND DOSING REGIMENS FOR TREATING OR PREVENTING INTERFERON-GAMMA RELATED INDICATIONS
The disclosure relates generally to methods compositions and dosing regimens for treating, preventing and/or delaying the onset or progression of, or...
2018/0142014 ULTRA-POTENT NEUTRALIZATION OF CYTOKINES BY MULTISPECIFIC ANTIBODIES AND USES THEREOF
The present invention provides multispecific antibodies, and antigen binding fragments thereof, that potently neutralize a cytokine and that may thus be useful...
2018/0142013 ANTI-GDF15 ANTIBODIES
Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including...
2018/0142012 INHIBITION OF THE SYNTHESIS OF BETA-APP OR OF THE ACTIVITY OF THE A-BETA PEPTIDE IN THE CHOROID PLEXUS
The invention relates to the treatment of neurodegenerative diseases, in particular Alzheimer's disease, by inhibition of the synthesis of .beta.APP or of the...
2018/0142011 Antibodies to Pyroglutamate Amyloid-B and Uses Thereof
The invention provides an antibody or antigen binding fragments thereof that binds to 3pE A.beta. and methods of making and using the antibody or antigen...
2018/0142010 METHOD FOR TREATING A PATIENT IN COMPLIANCE WITH VACCINATION WITH ECULIZUMAB OR AN ECULIZUMAB VARIANT
The present disclosure relates to, inter alia, a method of treating a patient in need of treatment with a C5 inhibitor or a method for inhibiting formation of...
2018/0142009 Specific Detection of Clusterin Isoforms
The invention provides methods and compositions for the detection of specific isoforms of clusterin.
2018/0142008 DYNAMIN 2 INHIBITOR FOR THE TREATMENT OF DUCHENNE'S MUSCULAR DYSTROPHY
The present disclosure relates to an inhibitor of Dynamin 2 or composition comprising the same for use in the treatment of Duchenne's muscular dystrophy.
2018/0142007 HUMANIZED TAU ANTIBODIES IN ALZHEIMER'S DISEASE
The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment Provided herein are...
2018/0142006 ANTIBODY PRODUCING NON-HUMAN ANIMALS
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human,...
2018/0142005 ANTIBODY PRODUCING NON-HUMAN ANIMALS
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human,...
2018/0142004 ANTIBODY PRODUCING NON-HUMAN ANIMALS
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human,...
2018/0142003 ANTIBODY PRODUCING NON-HUMAN ANIMALS
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human,...
2018/0142002 ANTIBODY PRODUCING NON-HUMAN ANIMALS
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human,...
← Previous | 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 | Next →

File A Patent Application

  • Protect your idea -- Don't let someone else file first. Learn more.

  • 3 Easy Steps -- Complete Form, application Review, and File. See our process.

  • Attorney Review -- Have your application reviewed by a Patent Attorney. See what's included.